Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPI Molecular Glue
- Development stage
- Preclinical
- Lead developer
- Beta Pharma
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral
01
Overview
BPI Molecular Glue is a preclinical-stage small molecule therapeutic being developed by Beta Pharma Technologies. It utilizes a molecular glue modality designed to mediate the modulation or degradation of disease-relevant proteins, specifically for the treatment of solid tumors. Molecular glues function by inducing or stabilizing interactions between an E3 ubiquitin ligase and a target protein, leading to the target's ubiquitination and subsequent proteasomal degradation. As of the current pipeline status, the specific protein target for this program has not been disclosed by the developer.
- Other names
- BPI Molecular Glue
Beyond the preview
Go deeper on BPI Molecular Glue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPI Molecular Glue.